Physician profile
Derek Harman
NPI 1326206749
$918.32
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $378 · 2021: $38.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $140.97 | 2019-2021 | |
| Glaxosmithkline, LLC. | $105.17 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $87.53 | 2019-2020 | |
| Amgen INC. | $85.19 | 2019 | |
| Novo Nordisk INC | $85.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.27 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.32 | 2019-2020 | |
| Allergan, INC. | $47.28 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.16 | 2019 | |
| Abbvie INC. | $28.36 | 2019 | |
| Merck Sharp & Dohme LLC | $24.50 | 2019-2020 | |
| Esperion Therapeutics, INC. | $17.91 | 2020 | |
| Genentech USA, INC. | $14.67 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $14.48 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.74 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Harman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.